Detected
PPCBNasdaq Trader
Propanc Biopharma, Inc. sets 1-for-25 reverse split for Monday, May 18, 2026
Listing RiskvolatileImpact60
PPCB Price
Stored market data$1.43-$0.02 (-1.38%)
Why It Matters
Holders will own fewer, higher-priced shares which preserves market cap but usually reduces liquidity, can widen spreads, and may create fractional cash-outs.
Propanc Biopharma will consolidate its common stock at a one-for-twenty-five ratio effective May 18, 2026. Current holders will receive one new share for each 25 old shares (fraction treatment likely cash), leaving market cap unchanged but reducing outstanding share count and public float.
Bullish
- Higher per-share price can improve perceived listing quality.
- Smaller share count can simplify the cap table.
Bearish
- Post-split float shrinks, likely lowering liquidity and widening bid-ask spreads.
- Reverse splits often signal listing pressure or distress, which can hurt demand.
- Fractional-share cash settlements can slightly reduce small-holder exposure.
Key Evidence
- Nasdaq notice: 1-for-25 reverse split effective May 18, 2026.
- Reported shares outstanding ~874,371 and price about $2.00 pre-split (market data).
What To Watch Next
- Company or broker details on fractional-share cash-out treatment.
- Immediate post-split intraday liquidity and bid-ask spreads.
- Any SEC filings or company statements explaining the split rationale.
- Option adjustments or temporary trading halts around the effective date.
AdvertisementResponsive display
AdvertisementResponsive display
Biotechnology Market Context
SectorHealthcare+0.70%
IndustryBiotechnology-1.26%